The cellular contents in bacteria are surrounded by an inner peptidoglycan cell wall in addition to an inner plasma membrane. Gram-negative bacteria also have an additional outer lipid bilayer. Specific antibacterials interfere with the synthesis of the cell wall, weakening the peptidoglycan scaffold within the bacterial wall, compromising the structural integrity. Since mammalian cells have a plasma membrane but lack the peptidoglycan wall structure, this class of antibacterials selectively targets the bacteria with no significant negative effect on the cells of the mammalian host.
Antibiotics that affect the structure of the cell wall act at different stages of peptidoglycan synthesis and cell wall construction. The precursor for the synthesis of peptidoglycan is a muramyl pentapeptide containing a terminal D-Ala-D-Ala. D-cycloserine inhibits two enzymes involved in the precursor synthesis, preventing both conversion of L-alanine to D-alanine by racemase, and the construction of D-alanyl-D-alanine by D-Ala-D-Ala ligase. In the cytoplasm, muramyl pentapeptide is anchored via a water-soluble UDP-glucosamine moiety. In the second phase of peptidoglycan construction, muramyl pentapeptide N-acetylglucosamine (muramyl pentapeptide anchored via a water-soluble UDP-glucosamine moiety) is transferred to a C55 undecaprenyl phosphate with the release of UMP to form a Lipid I intermediate. Tunicamycin inhibits the enzymatic conversion of the undecaprenyl phosphate to the lipid I intermediate, thus blocking the completion of peptidoglycan structure. An additional glycosylation step completes a peptidoglycan unit that is transported via its C55 lipid tail to the external periplasmic surface of the membrane. It is here that the peptidoglycan unit becomes integrated into the cell wall matrix. Bacitracin inhibits lipid phosphatase, preventing the release of the finished peptidoglycan from its C55 lipid carrier. Several transpeptidases and transglycosylases connect the newly formed peptidoglycan structures to the cell wall peptidoglycan matrix. ß-Lactam antibiotics (example Penicillin), with their structural similarity to the D-alanyl-D-alanine group within the peptidoglycan structure, compete for the binding sites of transpeptidases and prevent the assembly of the peptidoglycan layer in both Gram-positive and Gram-negative bacteria. Vancomycin, a glycopeptide antibiotic with a significantly larger structure than Penicillin, also prevents cell wall construction by interfering with transglycosylases. Its effectiveness is limited to Gram-positive bacteria because its large size prevents its penetration to the outer cytoplasmic membrane of Gram-negative bacteria. |
Product # | Description | Add to Cart |
---|
05260 | L-Alanyl-L-1-aminoethylphosphonic acid ≥98.0% (T) | | | A8398 | 7-Aminodesacetoxycephalosporanic acid | | | C3809 | Ceftazidime hydrate ≥90.0%, contains 10% sodium carbonate as stabilizer | | | E4632 | Econazole nitrate salt | | | E4630 | Ethambutol dihydrochloride antimycobacterial | | | L4402 | Lysostaphin from Staphylococcus staphylolyticus BioUltra, ≥97% (SDS-PAGE), Protein 40-60 % by biuret, ≥2,000 units/mg protein | | | L2898 | Lysostaphin from Staphylococcus staphylolyticus aseptically filled | | | L7386 | Lysostaphin from Staphylococcus staphylolyticus lyophilized powder, Protein 50-70 % by biuret, ≥500 units/mg protein | | | P7903 | Pipemidic acid | | | V2002 | 万古霉素 盐酸盐 来源于东方链霉菌 potency: ≥900 μg per mg (as vancomycin base) | | | N7878 | 呋喃妥因 crystalline | | | 46502 | 呋喃妥因 VETRANAL™, analytical standard | | | M8158 | 拉氧头孢 钠盐 analytical standard | | | 191140 | 7-氨基头孢烷酸 98% | | | A70909 | (+)-6-氨基青霉烷酸 96% | | | A9518 | 氨苄西林 钠盐 | | | P4875 | D-青霉胺 98-101% | |
|